Diane K Reyes

List of Publications by Year
in descending order

26	1,531	516710 16	610901 24
papers	citations	h-index	g-index

27	27	27	2131
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology, 2022, 39, 63.	2.5	6
2	CTâ€based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castrationâ€resÃ¯ve oligometastatic prostate cancer. Prostate, 2021, 81, 127-134.	2.3	9
3	Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer. Medical Oncology, 2021, 38, 80.	2.5	2
4	Prospective Comparison of PET Imaging with PSMA-Targeted ¹⁸F-DCFPyL Versus Na¹⁸F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 183-188.	5.0	27
5	Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Medical Oncology, 2020, 37, 60.	2.5	12
6	The combination of sizeâ€based separation and selectionâ€free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer. BJU International, 2020, 126, 191-201.	2.5	7
7	PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urology Case Reports, 2019, 23, 72-74.	0.3	5
8	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	2.2	21
9	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5020-5020.	1.6	2
10	Comparison of quantitative Yâ€90 SPECT and nonâ€timeâ€ofâ€flight PET imaging in postâ€therapy radioembolization of liver cancer. Medical Physics, 2016, 43, 5779-5790.	3.0	32
11	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.3	0
12	The biology and treatment of oligometastatic cancer. Oncotarget, 2015, 6, 8491-8524.	1.8	243
13	Oligometastatic Prostate Cancer to the Navicular Bone: Case Report. Urology Case Reports, 2015, 3, 59-62.	0.3	2
14	Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology, 2015, 277, 594-603.	7.3	31
15	Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. European Radiology, 2015, 25, 380-390.	4.5	24
16	Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury. CardioVascular and Interventional Radiology, 2013, 36, 449-459.	2.0	91
17	Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival. Radiology, 2013, 266, 502-513.	7.3	54
18	Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part II. Response Stratification Using Volumetric Functional Criteria after Intraarterial Therapy. Radiology, 2013, 268, 431-439.	7.3	49

#	Article	IF	Citations
19	Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional Response Criteria. Radiology, 2013, 268, 420-430.	7.3	41
20	Prospective phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Efficacy analysis.. Journal of Clinical Oncology, 2013, 31, 4124-4124.	1.6	0
21	Islet Cell Liver Metastases: Assessment of Volumetric Early Response with Functional MR Imaging after Transarterial Chemoembolization. Radiology, 2012, 264, 97-109.	7.3	40
22	Intrahepatic Cholangiocarcinoma Treated with Local-Regional Therapy: Quantitative Volumetric Apparent Diffusion Coefficient Maps for Assessment of Tumor Response. Radiology, 2012, 264, 285-294.	7.3	60
23	Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma. Journal of Clinical Oncology, 2011, 29, 3960-3967.	1.6	279
24	Unresectable Hepatocellular Carcinoma: Serial Early Vascular and Cellular Changes after Transarterial Chemoembolization as Detected with MR Imaging. Radiology, 2009, 250, 466-473.	7.3	178
25	Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2009, 15, 526-532.	2.0	121
26	The Role of Functional MR Imaging in the Assessment of Tumor Response after Chemoembolization in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2006, 17, 505-512.	0.5	195